Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 08, 2025 08:35 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

Preliminary data from the CATULUS Phase 1 trial of obe-cel in pediatric relapsed or refractory (r/r) B-ALL patients was presented at ASH 2025.
November 25, 2025 04:00 ET | Source: Autolus Therapeutics plc

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

the National Institute for Health and Care Excellence (NICE) has published draft guidance recommending AUCATZYL®.
November 12, 2025 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Autolus announced its operational and financial results for the third quarter ended September 30, 2025
May 23, 2025 08:30 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-ALL
May 08, 2025 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

Autolus announces its operational and financial results for the first quarter ended March 31, 2025.
January 13, 2025 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Provides Business Updates and 2025 Overview

Autolus announces business updates and an overview of 2025 milestones.
December 09, 2024 19:30 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
November 08, 2024 16:23 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia
November 05, 2024 09:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
April 25, 2022 07:01 ET | Source: Autolus Therapeutics plc

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult B-ALL

LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...